Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Medtronic Reports Positive Results From Symplicity Renal Denervation System

RELATED NEWS
Trade MDT now with 

Medtronic Inc (MDT: Quote) Friday announced positive results from the trial of its Simplicity Renal Denervation System.

The company stated that the six month pooled outcomes from randomized and crossover patients in the Simplicity HTN-2 clinical trial following renal denervation with the Simplicity renal denervation system showed significant and sustained reduction in blood pressure among those patients suffering with treatment-resistant hypertension.

Medtronic further noted that the pooled analysis included change in blood pressure at six months for all patients randomized to receive renal denervation with Symplicity at baseline (n=49), as well as patients in the control group (n=35) who met entry criteria and crossed over to the treatment group following assessment of the initial six month primary endpoint.

Renal denervation therapy is a minimally invasive, catheter-based procedure that modulates the output of nerves that lie within the renal artery wall and lead into and out of the kidneys. These nerves are part of the sympathetic nervous system, which affects the major organs that are responsible for regulating blood pressure: the brain, the heart, the kidneys and the blood vessels.

Click here to receive FREE breaking news email alerts for Medtronic Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Commercial bank holding company Citizens Financial Group, Inc. (CFG), owned by British lender Royal Bank of Scotland Group PLC (RBS, RBS.L), priced its initial public offering of 140 million shares at $21.50 per share, raising gross proceeds of about $3 billion. The pricing was below the company's estimated... Home goods retailer Bed Bath & Beyond Inc. said Tuesday after the markets closed that its second quarter profit fell 10% from last year, as higher costs and expenses more than offset a 4.3% increase in sales. However, the company's quarterly earnings per share came in above analysts' expectations as did its quarterly sales. At the same time, With lawmakers failing to address corporate tax reform before adjourning for the campaign season, the Treasury Department announced Monday that it is taking targeted action to reduce the tax benefits of corporate tax inversions.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.